Menu
Search
|

Menu

Close
X

aTyr Pharma Inc LIFE.OQ (NASDAQ Stock Exchange Global Select Market)

3.00 USD
-0.10 (-3.23%)
As of 2:29 AM IST
chart
Previous Close 3.10
Open 3.10
Volume 3,163
3m Avg Volume 7,949
Today’s High 3.10
Today’s Low 3.00
52 Week High 6.45
52 Week Low 2.33
Shares Outstanding (mil) 29.71
Market Capitalization (mil) 159.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.508
FY16
-2.444
FY15
-2.045
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
3.20
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
36.42
16.52
LT Debt to Equity (MRQ)
vs sector
29.46
12.22
Return on Investment (TTM)
vs sector
-75.04
14.43
Return on Equity (TTM)
vs sector
-82.03
16.13

EXECUTIVE LEADERSHIP

John Clarke
Independent Chairman of the Board, Since 2005
Salary: --
Bonus: --
Sanjay Shukla
President, Chief Executive Officer, Chief Medical Officer, Since 2017
Salary: $284,135.00
Bonus: $31,250.00
John Blake
Senior Vice President - Finance, Since 2017
Salary: --
Bonus: --
David King
Senior Vice President - Research, Since 2016
Salary: --
Bonus: --
Grove Matsuoka
Senior Vice President, Product Programs and Planning, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3545 John Hopkins Ct Ste 250
SAN DIEGO   CA   92121-1115

Phone: +1858.7318389

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

SPONSORED STORIES